Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
* Primary objective is to assess the safety of MG1111 until Day 42 using as 2nd vaccination * Secondary objective to assess the immunogenicity and safety of MG1111 using as 2nd vaccination
Epistemonikos ID: 27fc9d5dd59eae03eb9a569505a76a6b61dfdd2e
First added on: May 13, 2024